{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:35:50Z","timestamp":1754195750249},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:00:00Z","timestamp":1393286400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089732","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T22:04:28Z","timestamp":1393365868000},"page":"e89732","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Effect of Rosuvastatin on Inflammation, Matrix Turnover and Left Ventricular Remodeling in Dilated Cardiomyopathy: A Randomized, Controlled Trial"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00505154","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kaspar","family":"Broch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik T.","family":"Askevold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Godang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenche","family":"Stueflotten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Svendsmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00f8rgen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svend","family":"Aakhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,25]]},"reference":[{"key":"ref1","first-page":"1383","article-title":"Lancet","volume":"344","year":"1994"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"PM Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CRD.0b013e3181f52a7f","article-title":"The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review","volume":"18","author":"CG Mihos","year":"2010","journal-title":"Cardiol Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"PM Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"J Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"L Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.0000084539.58092.DE","article-title":"Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy","volume":"108","author":"K Node","year":"2003","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"S Sola","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.amjcard.2005.09.142","article-title":"Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels","volume":"97","author":"R Wojnicz","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref10","first-page":"MS12","article-title":"The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy","volume":"15","author":"A Bielecka-Dabrowa","year":"2009","journal-title":"Med Sci Monit"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.amjcard.2009.07.055","article-title":"Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure","volume":"104","author":"MJ Lipinski","year":"2009","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme\u2014 a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis","volume":"24","author":"JG Cleland","year":"2003","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"P Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"KF Schulz","year":"2010","journal-title":"BMC Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification","volume":"7","author":"RM Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ejechocard\/jer051","article-title":"Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes","volume":"12","author":"M Galderisi","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0894-7317(14)80005-9","article-title":"Visual assessment of valvular regurgitation: comparison with quantitative Doppler measurements","volume":"7","author":"JM Rivera","year":"1994","journal-title":"J Am Soc Echocardiogr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1530\/eje.1.02125","article-title":"Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency","volume":"154","author":"J Bollerslev","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: Analysing controlled trials with baseline and follow up measurements","volume":"323","author":"AJ Vickers","year":"2001","journal-title":"BMJ"},{"key":"ref20","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, <etal>et al<\/etal>.. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","article-title":"Inflammatory cytokines in heart failure: mediators and markers","volume":"122","author":"L Gullestad","year":"2012","journal-title":"Cardiology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2005.12.030","article-title":"Circulating markers of endothelial function in cardiovascular disease","volume":"368","author":"J Constans","year":"2006","journal-title":"Clin Chim Acta"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1050-1738(01)00160-8","article-title":"Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction","volume":"12","author":"J D'Armiento","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2004.01.010","article-title":"Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure","volume":"10","author":"M Cicoira","year":"2004","journal-title":"J Card Fail"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/CIRCHEARTFAILURE.110.958199","article-title":"Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure","volume":"4","author":"MR Zile","year":"2011","journal-title":"Circ Heart Fail"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","article-title":"Systemic inflammation in heart failure--the whys and wherefores","volume":"11","author":"A Yndestad","year":"2006","journal-title":"Heart Fail Rev"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"DX Bu","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/clc.4960251005","article-title":"Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study","volume":"25","author":"F Crea","year":"2002","journal-title":"Clin Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ajhp\/61.16.1676","article-title":"HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein","volume":"61","author":"KY Chan","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0735-1097(03)00263-8","article-title":"Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease","volume":"41","author":"T Waehre","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","article-title":"Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors","volume":"109","author":"T Waehre","year":"2004","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"JG Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.109.849117","article-title":"Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis","volume":"120","author":"JJ McMurray","year":"2009","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCHEARTFAILURE.110.957332","article-title":"Osteoprotegerin predicts progression of chronic heart failure: results from CORONA","volume":"4","author":"T Ueland","year":"2011","journal-title":"Circ Heart Fail"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/eurjhf\/hfs006","article-title":"Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology","volume":"14","author":"K Broch","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCHEARTFAILURE.112.972653","article-title":"Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"6","author":"ET Askevold","year":"2013","journal-title":"Circ Heart Fail"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cardfail.2006.09.008","article-title":"Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure","volume":"13","author":"H Krum","year":"2007","journal-title":"J Card Fail"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijcard.2009.12.028","article-title":"Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study","volume":"146","author":"E Ashton","year":"2011","journal-title":"Int J Cardiol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T23:49:27Z","timestamp":1565221767000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089732"}},"subtitle":[],"editor":[{"given":"Sudhiranjan","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,25]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089732","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,25]]}}}